Innovation Pharmaceuticals Inc (IPIX)

[ericseb2003]

I hear you. It's frustrating that Kevetrin has taken so long to advance through P1, and in the meantime we're seeing a lot of developments by our competition, particularly in the CAR-T and TCR cancer immunotherapy space (which have achieved amazing results so far in early clinical trials for various hematological (blood) cancers, but not yet proven in solid tumors - also some issues with side effects and lasting results).

However, it is what it is. Kevetrin has tremendous potential based on pre-clinical work, but it's going to take at least a 1.5 years, imho, before we get enough P2 data readouts to make a substantive call on its impact on humans. Have to hang our hats on B and P in the meantime.

Have to run, have a good one.